ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,422.34
-0.02%
Dow Jones
39,839.93
0.08%
Gold vs US Dollar
2,429.265
0.11%
Brent Oil
82.985
-0.65%
Bitcoin
70,200.82
-1.75%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Chemomab Therapeutics Ltd (CMMB)

  7. Chemomab Therapeutics Ltd (CMMB) News

Chemomab Therapeutics (CMMB)

Chemomab Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CMMB
DateTimeSourceHeadlineSymbolCompany
17/05/202412:00GlobeNewswire Inc.Chemomab Therapeutics to Participate in Upcoming Scientific ConferencesNASDAQ:CMMBChemomab Therapeutics Ltd
09/05/202412:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
09/05/202412:00GlobeNewswire Inc.Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
08/05/202412:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
08/05/202412:00GlobeNewswire Inc.Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleNASDAQ:CMMBChemomab Therapeutics Ltd
02/05/202412:00GlobeNewswire Inc.Chemomab Therapeutics to Present at 2024 Aegis Virtual ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
24/04/202412:00GlobeNewswire Inc.Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
18/04/202412:00GlobeNewswire Inc.Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisNASDAQ:CMMBChemomab Therapeutics Ltd
02/04/202412:00GlobeNewswire Inc.Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024NASDAQ:CMMBChemomab Therapeutics Ltd
25/03/202411:06GlobeNewswire Inc.Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
07/03/202412:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
07/03/202412:00PR Newswire (US)Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
05/03/202412:00PR Newswire (US)Chemomab Therapeutics to Participate in Leerink Global BioPharma ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
20/02/202414:20AllPennyStocks.comBiotech Shares Massively Bid Up Before Opening BellNASDAQ:CMMBChemomab Therapeutics Ltd
20/02/202412:00PR Newswire (US)Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesNASDAQ:CMMBChemomab Therapeutics Ltd
14/02/202412:00PR Newswire (US)Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
05/02/202412:00PR Newswire (US)Chemomab Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CMMBChemomab Therapeutics Ltd
30/01/202412:00PR Newswire (US)Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
03/01/202412:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
03/01/202412:00PR Newswire (US)Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024NASDAQ:CMMBChemomab Therapeutics Ltd
16/11/202312:00PR Newswire (US)Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic SclerosisNASDAQ:CMMBChemomab Therapeutics Ltd
15/11/202321:35Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CMMBChemomab Therapeutics Ltd
15/11/202312:00PR Newswire (US)Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
13/11/202313:00PR Newswire (US)Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023NASDAQ:CMMBChemomab Therapeutics Ltd
09/11/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
09/11/202313:00PR Newswire (US)Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
06/11/202321:15PR Newswire (US)Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price RequirementNASDAQ:CMMBChemomab Therapeutics Ltd
06/11/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMMBChemomab Therapeutics Ltd
30/10/202312:33Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:CMMBChemomab Therapeutics Ltd
30/10/202311:00PR Newswire (US)Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CMMB

Your Recent History

LSE
POS
Plexus
LSE
TERN
Tern
LSE
VAL
Valirx
LSE
VAST
Vast Resources
LSE
BP.
Bp
LSE
SCLP
Scancell
LSE
PHE
Powerhouse Energy
LSE
GKP
Gulf Keystone Petroleum
LSE
SYME
Supply@me Capital
LSE
MIN
Minoan
LSE
TEK
Tekcapital
LSE
SOLG
Solgold
LSE
KEFI
Kefi Gold And Copper
LSE
LLOY
Lloyds Banking
LSE
SCE
Surface Transforms
LSE
CHLL
Chill Brands
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved